Document is current
Any future updates will be listed below
-
Authors
Richeldi, Luca https://orcid.org/0000-0003-0506-9966
Azuma, Arata
Cottin, Vincent
Kreuter, Michael
Maher, Toby M https://orcid.org/0000-0001-7192-9149
Martinez, Fernando J
Oldham, Justin M
Valenzuela, Claudia https://orcid.org/0000-0002-0856-6290
Gordat, Maud
Liu, Yi
Stowasser, Susanne
Zoz, Donald F
Wijsenbeek, Marlies S
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct05321069 at ClinicalTrials.govnct05321069 at ClinicalTrials.govDocuments that mention this clinical trial
Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with idiopathic pulmonary fibrosis (FIBRONEER-IPF)
https://doi.org/10.1136/bmjresp-2022-001563
Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with progressive pulmonary fibrosis (FIBRONEER-ILD)
https://doi.org/10.1136/bmjresp-2022-001580
Rationale for phosphodiesterase-4 inhibition as a treatment strategy for interstitial lung diseases associated with rheumatic diseases
https://doi.org/10.1136/rmdopen-2024-004704
nct05321082 at ClinicalTrials.govDocuments that mention this clinical trial
Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with idiopathic pulmonary fibrosis (FIBRONEER-IPF)
https://doi.org/10.1136/bmjresp-2022-001563
Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with progressive pulmonary fibrosis (FIBRONEER-ILD)
https://doi.org/10.1136/bmjresp-2022-001580
Rationale for phosphodiesterase-4 inhibition as a treatment strategy for interstitial lung diseases associated with rheumatic diseases
https://doi.org/10.1136/rmdopen-2024-004704
Documents that mention this clinical trial
Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with idiopathic pulmonary fibrosis (FIBRONEER-IPF)
https://doi.org/10.1136/bmjresp-2022-001563
Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with progressive pulmonary fibrosis (FIBRONEER-ILD)
https://doi.org/10.1136/bmjresp-2022-001580
POS1300 DEMOGRAPHICS AND BASELINE CHARACTERISTICS OF PATIENTS WITH AUTOIMMUNE DISEASE INTERSTITIAL LUNG DISEASE ENROLLED IN THE FIBRONEER-ILD TRIAL OF BI 1015550
https://doi.org/10.1136/annrheumdis-2024-eular.1765
POS1329 DESIGN OF A PHASE III, RANDOMISED, PLACEBO-CONTROLLED TRIAL OF BI 1015550 IN PATIENTS WITH PROGRESSIVE FIBROSING INTERSTITIAL LUNG DISEASE
https://doi.org/10.1136/annrheumdis-2023-eular.897
Rationale for phosphodiesterase-4 inhibition as a treatment strategy for interstitial lung diseases associated with rheumatic diseases
https://doi.org/10.1136/rmdopen-2024-004704
-
Funding
Funding for this research was provided by:
Boehringer Ingelheim (N/A)
- License Information
